Compare Dover Corp (DOV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Novartis AG — how do they compare? Dover Corp trades at $207.91 (market cap $28.07B), while Novartis AG trades at $152.67 (market cap $295.37B). The key difference: Novartis AG is far larger — about 10.5× Dover Corp's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| DOV | NVS | |
|---|---|---|
Market Cap | $28.07B | $295.37B |
Sector | Industrials | Health |
52-Week High | $233.31 | $168.62 |
52-Week Low | $161.16 | $119.31 |
Enterprise Value | $29.58B | $336.69B |
Dividend Yield | 1.01% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $210.1, down 0.49% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong Q2 2026 results with EPS of $2.74, exceeding expectations, and raised full-year guidance. Recent dividend increases and strategic acquisitions, such as Cloeren, highlight management's confidence in growth. Valuation ratios like P/E of 25.21 and ROE of 14.98% reflect solid profitability, though the stock faces resistance near $212.
The outlook for DOV is positive, driven by robust fundamentals and analyst consensus favoring a buy rating with a $232.33 price target. Risks include market volatility and execution challenges from acquisitions, but diversified end-market exposure and margin expansion support upside potential for investors seeking steady income and growth.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
